Noam Benyamini

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Fredrik Schjesvold, Albert Oriol, Lionel Karlin et al. · The Lancet Haematology · 2019 · 242 citations · Full text

Medicine, Oncology, Pharmacology +11

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

Chava Perry, Efrat Luttwak, R. Balaban et al. · Blood Advances · 2021 · 170 citations · Full text

Veterinary Medicine, Immunology, Oncology +13

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study

Ron Ram, David Hagin, Nino Kikozashvilli et al. · Transplantation and Cellular Therapy · 2021 · 164 citations · Full text

Life Sciences, Hematology, Immunology +17

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

François-Xavier Mahon, Carla Boquimpani, Dong‐Wook Kim et al. · Annals of Internal Medicine · 2018 · 132 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11